See the DrugPatentWatch profile for vyvanse
What is the generic name for Vyvanse?
The primary active ingredient in Vyvanse is lisdexamfetamine dimesylate [1].
When will generic Vyvanse be available?
As of mid-2024, generic versions of Vyvanse are not yet available in the United States. The patent protecting Vyvanse is set to expire in the coming years, which would allow for generic competition [2].
What are the most searched-for alternatives to Vyvanse?
Patients often search for information on other ADHD medications, including Adderall and Ritalin, when considering alternatives to Vyvanse [3].
Can you get a generic version of lisdexamfetamine?
Currently, there is no generic version of lisdexamfetamine available. The drug is protected by patents [1, 2].
Why are companies challenging Vyvanse patents?
Companies may challenge patents for drugs like Vyvanse to try and bring generic versions to market sooner. These challenges often involve arguing that the patent should not have been granted or that their product does not infringe on the existing patent [4].
What is the difference between brand-name Vyvanse and generic lisdexamfetamine?
When a generic version becomes available, it will contain the same active ingredient, lisdexamfetamine dimesylate, in the same dosage and form as brand-name Vyvanse. Generic drugs are typically less expensive than their brand-name counterparts [5].
Who makes Vyvanse?
Vyvanse is manufactured by Takeda Pharmaceuticals [1].
What are the risks associated with lisdexamfetamine?
Lisdexamfetamine, like other amphetamines, carries risks including potential for abuse and dependence, cardiovascular issues, and psychiatric side effects [6].
What is the mechanism of action for Vyvanse?
Vyvanse is a prodrug that is converted to dextroamphetamine in the body. Dextroamphetamine works by increasing the levels of certain neurotransmitters, such as dopamine and norepinephrine, in the brain. This helps to improve focus and reduce impulsivity [1].
Sources:
[1] https://www.drugpatentwatch.com/drug/vyvanse
[2] https://www.drugpatentwatch.com/blogs/blog/vyvanse-patent-expiration-and-generic-competition
[3] https://www.drugpatentwatch.com/blogs/blog/vyvanse-alternatives-and-patient-searches
[4] https://www.drugpatentwatch.com/blogs/blog/understanding-patent-litigation-in-the-pharmaceutical-industry
[5] https://www.drugpatentwatch.com/blogs/blog/the-impact-of-generics-on-drug-pricing
[6] https://www.drugpatentwatch.com/blogs/blog/understanding-the-risks-and-side-effects-of-stimulant-medications